This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Genomics of deletion 7 and 7q in myeloid neoplasm: from pathogenic culprits to potential synthetic lethal therapeutic targets
Leukemia Open Access 26 August 2023
-
CRISPR/Cas9 genome-wide screening identifies LUC7L2 that promotes radioresistance via autophagy in nasopharyngeal carcinoma cells
Cell Death Discovery Open Access 14 December 2021
-
Cut-like homeobox 1 (CUX1) tumor suppressor gene haploinsufficiency induces apoptosis evasion to sustain myeloid leukemia
Nature Communications Open Access 30 April 2021
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Ernst T, Chase AJ, Score J, Hidalgo-Curtis CE, Bryant C, Jones AV et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet 2010; 42: 722–726.
Makishima H, Jankowska AM, Tiu RV, Szpurka H, Sugimoto Y, Hu Z et al. Novel homo- and hemizygous mutations in EZH2 in myeloid malignancies. Leukemia 2010; 24: 1799–1804.
Nikoloski G, Langemeijer SM, Kuiper RP, Knops R, Massop M, Tonnissen ER et al. Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nat Genet 2010; 42: 665–667.
Jerez A, Sugimoto Y, Makishima H, Verma A, Jankowska AM, Przychodzen B et al. Loss of heterozygosity in 7q myeloid disorders: clinical associations and genomic pathogenesis. Blood 119: 6109–6117.
Gomez-Segui I, Makishima H, Jerez A, Yoshida K, Przychodzen B, Miyano S et al. Novel recurrent mutations in the RAS-LIKE GTP-Binding gene RIT1 in myeloid malignancies. Leukemia 2013; 27: 1943–1946.
Kipreos ET, Lander LE, Wing JP, He WW, Hedgecock EM . cul-1 is required for cell cycle exit in C. elegans and identifies a novel gene family. Cell 1996; 85: 829–839.
Marti A, Wirbelauer C, Scheffner M, Krek W . Interaction between ubiquitin-protein ligase SCFSKP2 and E2F-1 underlies the regulation of E2F-1 degradation. Nat Cell Biol 1999; 1: 14–19.
Tamagnone L, Artigiani S, Chen H, He Z, Ming GI, Song H et al. Plexins are a large family of receptors for transmembrane, secreted, and GPI-anchored semaphorins in vertebrates. Cell 1999; 99: 71–80.
Khan SN, Jankowska AM, Mahfouz R, Dunbar AJ, Sugimoto Y, Hosono N et al. Multiple mechanisms deregulate EZH2 and histone H3 lysine 27 epigenetic changes in myeloid malignancies. Leukemia 2013; 27: 1301–1309.
Howell VM, Jones JM, Bergren SK, Li L, Billi AC, Avenarius MR et al. Evidence for a direct role of the disease modifier SCNM1 in splicing. Hum Mol Genet 2007; 16: 2506–2516.
Singh H, Lane AA, Correll M, Przychodzen B, Sykes DB, Stone RM et al. Putative RNA-splicing gene LUC7L2 on 7q34 represents a candidate gene in pathogenesis of myeloid malignancies. Blood Cancer J 2013; 3: e117.
Nepveu A . Role of the multifunctional CDP/Cut/Cux homeodomain transcription factor in regulating differentiation, cell growth and development. Gene 2001; 270: 1–15.
Hulea L, Nepveu A . CUX1 transcription factors: from biochemical activities and cell-based assays to mouse models and human diseases. Gene 2012; 497: 18–26.
Thoennissen NH, Lasho T, Thoennissen GB, Ogawa S, Tefferi A, Koeffler HP . Novel CUX1 missense mutation in association with 7q- at leukemic transformation of MPN. Am J Hematol 2011; 86: 703–705.
Cadieux C, Fournier S, Peterson AC, Bedard C, Bedell BJ, Nepveu A . Transgenic mice expressing the p75 CCAAT-displacement protein/Cut homeobox isoform develop a myeloproliferative disease-like myeloid leukemia. Cancer Res 2006; 66: 9492–9501.
Acknowledgements
We thank the Cancer Genome Atlas (TCGA) for providing access to the whole-genome sequencing results described in the text. This work is supported by the National Institutes of Health (NIH; Bethesda, MD, USA) grants RO1 HL082983 (JPM), U54 RR019391(JPM and MAS) and K24 HL077522(JPM); AA & MDS International Foundation (Rockville, MD, USA; HM) and Scott Hamilton CARES grant (Cleveland, OH, USA; HM).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies this paper on the Leukemia website
Supplementary information
Rights and permissions
About this article
Cite this article
Hosono, N., Makishima, H., Jerez, A. et al. Recurrent genetic defects on chromosome 7q in myeloid neoplasms. Leukemia 28, 1348–1351 (2014). https://doi.org/10.1038/leu.2014.25
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2014.25
This article is cited by
-
Genomics of deletion 7 and 7q in myeloid neoplasm: from pathogenic culprits to potential synthetic lethal therapeutic targets
Leukemia (2023)
-
Immunohistochemical loss of enhancer of Zeste Homolog 2 (EZH2) protein expression correlates with EZH2 alterations and portends a worse outcome in myelodysplastic syndromes
Modern Pathology (2022)
-
Cut-like homeobox 1 (CUX1) tumor suppressor gene haploinsufficiency induces apoptosis evasion to sustain myeloid leukemia
Nature Communications (2021)
-
CRISPR/Cas9 genome-wide screening identifies LUC7L2 that promotes radioresistance via autophagy in nasopharyngeal carcinoma cells
Cell Death Discovery (2021)
-
Impact of somatic mutations in myelodysplastic patients with isolated partial or total loss of chromosome 7
Leukemia (2020)